Inflammation-Driven Genomic Instability: A Pathway to Cancer Development and Therapy Resistance
Pharmaceuticals · 18.09.2025 · 18 (9) · 1406
DOI: 10.3390/ph18091406 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 18.09.2025. Verfasst von Nina Rembiałkowska und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Biology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Statutory Subsidy Funds of the Department of Molecular and Cellular Biology, Students’ Research Group of Cancer Cell Biology of the Department of Molecular and Cell Biology of the Wroclaw Medical University.
Abstract (Originalsprache)
Chronic inflammation, while originally a protective physiological response, is increasingly recognized as a key contributor to carcinogenesis. Prolonged inflammatory signaling leads to the sustained production of reactive oxygen and nitrogen species (ROS/RNS), resulting in direct and indirect DNA damage, including base modifications, strand breaks, and DNA cross-linking. Simultaneously, pro-inflammatory mediators such as NF-κB, IL-6, and TNF-α can interfere with DNA repair mechanisms, altering the efficiency of key pathways such as base excision and mismatch repair. Immune cells infiltrating chronically inflamed tissues, including macrophages and neutrophils, further exacerbate genomic instability through ROS/RNS release and cytokine production, creating a tumor-promoting microenvironment. Additionally, chronic inflammation has been implicated in the development of resistance to chemotherapy and radiotherapy by modulating DNA damage response pathways. Understanding the interplay between inflammation, genomic instability, and therapy resistance provides a framework for novel treatment strategies. Targeting chronic inflammation with non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or biological agents such as monoclonal antibodies offers promising avenues for cancer prevention and treatment. Targeting inflammation with NSAIDs, corticosteroids, and monoclonal antibodies shows promise in cancer prevention and therapy, particularly in lung and pancreatic cancer. These agents act by blocking key inflammatory pathways like COX-2, NF-κB, and cytokine signaling. However, potential adverse effects require further clinical evaluation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular and Cellular Biology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.
- Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland.
ORCID-Profile: Nina Rembiałkowska, Maja Kübler, Mikołaj Sędzik, Agnieszka Gajewska-Naryniecka
Förderung
- Statutory Subsidy Funds of the Department of Molecular and Cellular Biology
- Students’ Research Group of Cancer Cell Biology of the Department of Molecular and Cell Biology of the Wroclaw Medical University
Zitieren
APA
Rembiałkowska, N., Kocik, Z., Kłosińska, A., Kübler, M., Pałkiewicz, A., Rozmus, W., Sędzik, M., Wojciechowska, H., & Gajewska-Naryniecka, A. (2025). Inflammation-Driven Genomic Instability: A Pathway to Cancer Development and Therapy Resistance. Pharmaceuticals, 18(9), 1406. https://doi.org/10.3390/ph18091406
Vancouver
Rembiałkowska N, Kocik Z, Kłosińska A, Kübler M, Pałkiewicz A, Rozmus W, et al. Inflammation-Driven Genomic Instability: A Pathway to Cancer Development and Therapy Resistance. Pharmaceuticals. 2025;18(9):1406. doi:10.3390/ph18091406
BibTeX
@article{Rembiakowska2025,
author = {Rembiałkowska, Nina and Kocik, Zofia and Kłosińska, Amelia and Kübler, Maja and Pałkiewicz, Agata and Rozmus, Weronika and Sędzik, Mikołaj and Wojciechowska, Helena and Gajewska-Naryniecka, Agnieszka},
title = {Inflammation-Driven Genomic Instability: A Pathway to Cancer Development and Therapy Resistance},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {9},
pages = {1406},
doi = {10.3390/ph18091406}
}
EUVIMED